thalidomide has been researched along with Bacteremia in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Bacteremia: The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide, an agent which inhibits biosynthesis of tumor necrosis factor alpha (TNF-alpha) and which is used to treat a variety of chronic inflammatory conditions, was investigated as therapy for experimental sepsis." | 7.72 | Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide. ( Dontas, I; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Kostomitsopoulos, N; Perrea, D; Poulaki, H, 2003) |
| "Thalidomide, an agent which inhibits biosynthesis of tumor necrosis factor alpha (TNF-alpha) and which is used to treat a variety of chronic inflammatory conditions, was investigated as therapy for experimental sepsis." | 3.72 | Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide. ( Dontas, I; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Kostomitsopoulos, N; Perrea, D; Poulaki, H, 2003) |
| "Thalidomide treatment did not protect normal mice from death but decreased remote lesion occurrence, with concurrent reduced bacterial counts recoverable from blood." | 1.33 | Lethal outcome caused by Porphyromonas gingivalis A7436 in a mouse chamber model is associated with elevated titers of host serum interferon-gamma. ( Hu, SW; Huang, JH; Lai, YY; Lin, YY, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giamarellos-Bourboulis, EJ | 1 |
| Poulaki, H | 1 |
| Kostomitsopoulos, N | 1 |
| Dontas, I | 1 |
| Perrea, D | 1 |
| Karayannacos, PE | 1 |
| Giamarellou, H | 1 |
| Huang, JH | 1 |
| Lin, YY | 1 |
| Lai, YY | 1 |
| Hu, SW | 1 |
2 other studies available for thalidomide and Bacteremia
| Article | Year |
|---|---|
Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide.
Topics: Animals; Bacteremia; Cytokines; Escherichia coli Infections; Female; Humans; Immunosuppressive Agent | 2003 |
Lethal outcome caused by Porphyromonas gingivalis A7436 in a mouse chamber model is associated with elevated titers of host serum interferon-gamma.
Topics: Animals; Antibodies; Bacteremia; Bacteroidaceae Infections; Cause of Death; Colony Count, Microbial; | 2006 |